Structure Therapeutics’ oral obesity drug elicited a placebo-adjusted weight loss of 16.3% at 44 weeks in a Phase 2 trial.
Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an ...
Testing revealed weight loss effects some Wall Street analysts believe compare favorably to Lilly’s orforglipron, which ...
Structure Therapeutics Inc.’s shares rose after more data on the company’s experimental weight-loss pill showed it’s shaping ...
Structure Therapeutics' oral obesity drug aleniglipron delivered up to 16.3% weight loss when compared with a placebo after ...
Structure Therapeutics (GPCR) stock jumped 10% after its GLP-1 pill aleniglipron posted 16.3% weight loss, outperforming Lilly and Novo's oral candidates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results